Investigation Launched into Applied Therapeutics
Glancy Prongay & Murray LLP, a respected national shareholder rights law firm, has announced the start of an investigation concerning Applied Therapeutics, Inc. This investigation focuses on the possible violations of federal securities laws that may have affected investors significantly.
Concerns Addressed by the Investigative Team
For individuals who have experienced financial losses on their investments in Applied Therapeutics, there may be potential avenues to recover those losses. It is advised to explore claims under the federal securities laws. Investors are encouraged to provide their contact information to begin the process of seeking redress for any losses incurred.
How to Connect with the Legal Team
If you believe you qualify for properties under these legal inquiries, reach out to the firm for further information. Charles H. Linehan at GPM can be contacted by phone or directly through their official site for assistance and to understand your rights.
Recent Developments in Applied Therapeutics
A significant development occurred recently when Applied Therapeutics disclosed that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) concerning a New Drug Application for govorestat, a treatment for Classic Galactosemia. The response letter indicated that the FDA could not approve the application in its current form, calling attention to deficiencies that must be addressed.
Impact on Stock Prices
The news triggered a sharp decline in Applied Therapeutics’ stock price, which saw a staggering drop of over 76% shortly after the announcement. This rapid decline in value raised concerns among investors about the future of their investments in the company.
Social Media Updates and Communication
Individuals interested in staying informed about updates from Glancy Prongay & Murray LLP can follow the firm on various social media platforms such as LinkedIn, Twitter, and Facebook. This allows investors to remain educated on developments surrounding their investments.
Whistleblower Information
In addition to the ongoing investigation, individuals with non-public information regarding Applied Therapeutics are urged to consider stepping forward to aid the investigation. Utilizing the SEC Whistleblower Program could grant whistleblowers the chance to receive substantial rewards should the information contribute to a successful recovery.
About Glancy Prongay & Murray LLP
Glancy Prongay & Murray LLP has built a reputation as a leading firm handling important litigation cases. With nearly 40 attorneys attending to a broad array of class action cases, the firm has achieved notable recoveries across various sectors. Their documented history includes dealings with corporate fraud, securities violations, and numerous successful class action settlements.
Frequently Asked Questions
What is the purpose of the investigation by GPM?
The investigation seeks to determine if Applied Therapeutics violated federal securities laws, potentially harming investors.
How can I know if I qualify for a claim?
If you suffered financial losses from your investment in Applied Therapeutics, reaching out to the legal team can provide clarity on your eligibility.
What happened with the FDA and Applied Therapeutics?
Applied Therapeutics received a Complete Response Letter from the FDA stating that their drug application could not be approved in its current form due to deficiencies.
How did the stock price react to the FDA news?
The stock price of Applied Therapeutics fell dramatically by over 76% following the news of the FDA's response.
Who can I contact for more information?
You can contact Charles H. Linehan from Glancy Prongay & Murray LLP directly for more information regarding the investigation and your rights.
